Market Research Reports and Industry Reports

Xtandi- The Real Potential and the Astellas Part!

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION
Xtandi- The Real Potential and the Astellas Part!

Expectations that Xtandi (Enzalutamide, Approved, Prostate Cancer) is going to bring a paradigm shift to treat prostate cancer as an ideal antiandrogen therapy (includes positive expectation from interim analysis of PREVAIL expected at ESMO-13/ early 4Q 2013 study in pre-chemo setting) has recently resulted in a rally in Astellas price. Although, the clinical profile of Xtandi (steroid free regimen, better safety and efficacy than Zytiga) carries potential to compete with Casodex/Zytiga generics post 2016, we think that emerging new candidates (ARN-509, ODM-021, TAK-700) create some threat for Xtandi and the agreement between Astellas and Medivation is not lucrative enough for Astellas. Xtandis major sales will come from metastatic pre-chemo setting due to
Pre-chemo vs. Post chemo Market size: Metastatic Pre chemo market 3 times bigger than post chemo; Zytiga 1Q 2013 sales reveal this basis
N/A

List Of Tables

N/A

List Of Figures

N/A

Xtandi-API Insights, 2017

The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large

USD 500View Report

Xtandi- The Real Potential and the Astellas Part!

Xtandi- The Real Potential and the Astellas Part!Expectations that Xtandi (Enzalutamide, Approved, Prostate Cancer) is going to bring a paradigm shift to treat prostate cancer as an ideal antiandrogen therapy

USD 500View Report

The Real Good Food Company plc - Strategy, SWOT and Corporate Finance Report

The Real Good Food Company plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the companys structure, operation, SWOT

USD 175View Report

The Real-time policy management: mobile broadband and new technology will drive CSPs’ revenue growth

CSPs reliance on revenue from traditional voice and messaging services has significantly impacted their operations, with most CSPssupport systems unable to keep up with developing market conditions. CSPs have been

USD 1499View Report

The Real-time decisioning from Emagine International helps a CSP to improve ARPU

A Tier 1 CSP in the Middle East and North Africa region has deployed Emagine International Dynamic Deals solution, to support its aim of delivering personalised offers to its customers

USD 999View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
Country Code.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    $ 500
  • Site Licence    $ 1000
  • Enterprisewide Licence    $ 1500
$ 500

Reports Details

Published Date : Apr 2013
No. of Pages :12
Country :Global
Category :Healthcare
Publisher :MP Advisors
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube
,
seo teknikleri wordpress ücretsiz tema istanbul sexs shop hacklink e sigara sexs shop
bostancı escort pendik escort kurtköy escort etiler escort şirinevler escort ankara escort ankara escort bayan escort ankara beylikdüzü escort avcılar escort ankara escort bayan